Time to failure of oral therapy in children with type 2 diabetes: A single center retrospective chart review

Pediatric Diabetes

Volumn 13, Issue 7, 2012, Pages 578-582

  Barnes, Nicole S ^a   White, Perrin C ^a   Hutchison, Michele R ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Insulin; Metformin; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; INSULIN; METFORMIN;

ADOLESCENT; ADULT; ARTICLE; BODY MASS; CHILD; CLINICAL ASSESSMENT; DRUG TOLERABILITY; FEMALE; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENCE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RACE; RETROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT DURATION; TREATMENT FAILURE;

ADMINISTRATION, ORAL; ADOLESCENT; BLOOD GLUCOSE; CHILD; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; KAPLAN-MEIER ESTIMATE; METFORMIN; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES;

EID: 84868204718     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/j.1399-5448.2012.00873.x     Document Type: Article

References (12)

1. SEARCH for Diabetes in Youth Study Group, Liese AD, D'Agostino RB Jr, Hamman RF et al. The burden of diabetes mellitus among US youth: prevalence estimates from the SEARCH for Diabetes in Youth Study. Pediatrics 2006: 118: 1510-1518.
2. Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. JAMA 2003: 13: 1884-1890.
3. Rapaport R, Silverstein JH, Garzarella L, Rosenbloom AL. Type 1 and type 2 diabetes mellitus in childhood in the United States: practice patterns by pediatric endocrinologists. J Pediatr Endocrinol Metab 2004: 17: 871-877.
4. Shield JPH, Lynn R, Wan KC, Haines L, Barrett TG. Management and 1year outcome for UK children with type 2 diabetes. Arch Dis Child 2009: 94: 206-209.
5. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2010: 33: S11-S61.
6. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of Rosiglitazone, Metformin, or Glyburide Monotherapy (ADOPT). NEJM 2006: 355: 2427-2443.
7. Brown JB, Conner C, Nichols GA. Secondary failure of metformin monotherapy in clinical practice. Diabetes Care 2010: 33: 501-506.
8. Nichols GA, Alexander CM, Girman CJ, Kamal-Bahl SJ, Brown JB. Treatment escalation and rise in HbA1c following successful initial metformin therapy. Diabetes Care 2006: 3: 504-509.
9. Turner R, Cull C, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS). JAMA 1999: 281: 2005-2012.
10. Rothman RL, Mulvaney S, Elasy TA, et al. Self-management behaviors, racial disparities, and glycemic control among adolescents with type 2 diabetes. Pediatrics 2008: 121: e912-919.
11. Davis TME, Wright AD, Mehta ZM, et al. Islet autoantibodies in clinically diagnosed type 2 diabetes; prevalence and relationship with metabolic control (UKPDS 70). Diabetologia 2005: 48: 695-702.
12. Bottazzo GF, Bosi E, Cull CA, et al. IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71). Diabetologia 2005: 48: 703-708.